<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>anca.knit</title>

<script src="site_libs/header-attrs-2.28/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>







<link rel="stylesheet" href="styles.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}

.tocify-subheader {
  display: inline;
}
.tocify-subheader .tocify-item {
  font-size: 0.95em;
}

</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Renal Medicine</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Research
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./trials.html">Metro North KHS Trials</a>
    </li>
    <li>
      <a href="./Research_MN_output.html">Metro North KHS Research output</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GEN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HTN.html">HTN</a>
    </li>
    <li>
      <a href="./CCF.html">CCF</a>
    </li>
    <li>
      <a href="./DKD.html">DKD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    U&amp;E
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./acidbase.html">H+ &amp; HCO3</a>
    </li>
    <li>
      <a href="./na.html">Na</a>
    </li>
    <li>
      <a href="./k.html">K</a>
    </li>
    <li>
      <a href="./mg.html">MG</a>
    </li>
    <li>
      <a href="./renalbone.html">Ca2+ &amp; PO4</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./MCD.html">MCD</a>
    </li>
    <li>
      <a href="./ANCA.html">ANCA</a>
    </li>
    <li>
      <a href="./IGAN.html">IGAN</a>
    </li>
    <li>
      <a href="./MPGN_C3G.html">MPGN &amp; C3G</a>
    </li>
    <li>
      <a href="./LUPUS.html">LUPUS</a>
    </li>
    <li>
      <a href="./FSGS.html">FSGS</a>
    </li>
    <li>
      <a href="./TMA.html">TMA</a>
    </li>
    <li>
      <a href="./GBM.html">GBM</a>
    </li>
    <li>
      <a href="./MN.html">MN</a>
    </li>
    <li>
      <a href="./Amyloid.html">Amyloid</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    CKD
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Checklist</a>
    </li>
    <li>
      <a href="./project1.html">Conservative care</a>
    </li>
    <li>
      <a href="./anaemia.html">Anaemia</a>
    </li>
    <li>
      <a href="./project1.html">Pruritis</a>
    </li>
    <li>
      <a href="./renalbone.html">CKD-MBD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    TX
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Cheat sheet</a>
    </li>
    <li>
      <a href="./txnotes.html">Misc Notes</a>
    </li>
    <li>
      <a href="./nonkidneytx.html">Non Kidney Tx</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    RRT
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HD.html">HD</a>
    </li>
    <li>
      <a href="./project1.html">Home HD</a>
    </li>
    <li>
      <a href="./project1.html">HD Access</a>
    </li>
    <li>
      <a href="./project1.html">PD</a>
    </li>
    <li>
      <a href="./project1.html">CVVH</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    DRUGS
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./anticoagulation.html">Anticoagulation</a>
    </li>
    <li>
      <a href="./PJP.html">PJP</a>
    </li>
    <li>
      <a href="./abx.html">Abx</a>
    </li>
    <li>
      <a href="./aboutme.html">HDU</a>
    </li>
    <li>
      <a href="./project1.html">Flozins</a>
    </li>
    <li>
      <a href="./rituxcyc.html">RITUX &amp; CYC</a>
    </li>
    <li>
      <a href="./Chemotherapy.html">Chemo</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    MISC
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./biopsy.html">Biopsy</a>
    </li>
    <li>
      <a href="./path.html">PATH</a>
    </li>
    <li>
      <a href="./preg.html">Pregnancy</a>
    </li>
    <li>
      <a href="./project1.html">PEX</a>
    </li>
    <li>
      <a href="./Lymphoproliferative.html">Lymphoproliferative</a>
    </li>
    <li>
      <a href="./covid19.html">SARS-Cov-2</a>
    </li>
    <li>
      <a href="./Tumour_Lysis.html">Tumour Lysis Syndrome</a>
    </li>
    <li>
      <a href="./Single Kidney.html">Single Kidney</a>
    </li>
    <li>
      <a href="./IGG4.html">IGG4</a>
    </li>
    <li>
      <a href="./Stones.html">Stones</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Resources
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./edu.html">Educational Resources</a>
    </li>
    <li>
      <a href="./patient_resources.html">Patient Resources</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https:eoindosullivan.com">
    <span class="fas fa-home"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">




</div>


<div class="float">
<img src="images/vasculitis.png"
alt="Jennette et al Arthritis Rheum 2013; 6544: 1-11" />
<div class="figcaption">Jennette et al Arthritis Rheum 2013; 6544:
1-11</div>
</div>
<div id="large-vessel" class="section level2">
<h2>Large Vessel</h2>
<p>A vessel you can see grossly – e.g. Aorta, major branches</p>
<ul>
<li><strong>Giant cell</strong>
<ul>
<li>Patient &gt;50</li>
<li>Previously known as temporal arteritis – bad name – doesn’t always
affect temporal arteries, and other vasculitis can affect Temporal
arteries (e.g. GPA)</li>
<li>Aortitis: Multinucleated giant cells, disrupts elastic fibres of
internal elastic lamina.</li>
<li>Can affect a Renal Artery – rare, very rarely causes renovascular
HTN.</li>
<li>Predilection for head and neck vessels</li>
</ul></li>
<li><strong>Takayasu</strong>
<ul>
<li>Patient &lt;50 (at time of onset)</li>
<li>Often granulomatous – histopathology often fairly similar to Giant
cell arteritis – no biomarkers currently, very challenging for path to
tell apart.</li>
<li>In contrast to GCA - Can often cause RAS and renovascular HTN</li>
<li>Aortitis – transmural inflammation</li>
</ul></li>
<li>Notes:
<ul>
<li>Fibrinoid Necrosis absent or minimal</li>
<li>Can’t really differentiate between Arteriosclerosis vs post
vasculitis – silver stain can help show the sclerosis.</li>
</ul></li>
</ul>
</div>
<div id="medium-vessel" class="section level2">
<h2>Medium Vessel</h2>
<p>Main visceral e.g. mesenteric, renal arteries, arcuate</p>
<ul>
<li><strong>Polyarteritis Nodosa</strong>
<ul>
<li>Necrotising arteritis of medium/small without GN or vasculitis in
arterioles, capillaries, or venules</li>
<li>Diagnosis of <strong>exclusion</strong> of Kawasaki and Small Vessel
Vasculitis</li>
<li>Therefore, must be ANCA negative (pathology indistinguishable)</li>
</ul></li>
<li><strong>Kawasaki</strong>
<ul>
<li>Initial name was “infantile PAN” in USA</li>
<li>Children &lt;3 &amp; infants</li>
<li>Mucocutaneous lymph node symptoms (erythema, mucosal sloughing,
nodes up)</li>
<li>Coronary predilection – MI major concern.</li>
<li>Aorta and large arteries may be involved.</li>
<li>Renal involvement less common a problem but often found on
postmortem</li>
</ul></li>
<li>Notes:
<ul>
<li>Necrotizing Arteritis is primary lesion.</li>
<li>Inflammatory aneurysm and stenoses are common.</li>
<li>Early: fibrinoid necrosis – 1 weeks later – scar/fibrosis</li>
</ul></li>
</ul>
</div>
<div id="small-vessel" class="section level2">
<h2>Small Vessel</h2>
<p>Microscopic vessels e.g. glomerular capillaries</p>
</div>
<div id="pauci-immune-anca" class="section level2">
<h2>Pauci Immune: ANCA</h2>
<ul>
<li>ANCA activates neuts and mono directly via PR3/MPO- &gt; amplified
by C3a, C5a (alternative complement)</li>
<li>Initial infiltration is neuts but replaced within a few days by
monocytes and macs.</li>
<li>Pauci =/= absence, you can find a little bit if you look, especially
on EM (e.g. microenvironment generation of complex?)</li>
<li>Can affect essentially <strong>any</strong> organ or tissue.</li>
<li>Best Practice: use a phenotype &amp; serotype i.e. MPO-ANCA MPA, or
PR3 ANCA MPA, ANCA-Negative GPA etc</li>
</ul>
<div id="phenotype" class="section level3">
<h3>Phenotype</h3>
<ul>
<li>Microscopic Polyangiitis aka MPA
<ul>
<li>No granulomas, no asthma</li>
</ul></li>
<li>Wegener’s Granulomatosis aka GPA
<ul>
<li>Granulomas, no Asthma</li>
</ul></li>
<li>Churg-Strauss Syndrome
<ul>
<li>Eosinophilia (~10%), Asthma, Granulomas</li>
</ul></li>
</ul>
<div class="float">
<img src="images/ANCA_serotype_phenotype_conversion.png"
alt="O’Shaughnessy MM et al, JASN 2017, 12:614-623" />
<div class="figcaption">O’Shaughnessy MM et al, JASN 2017,
12:614-623</div>
</div>
</div>
<div id="serotype" class="section level3">
<h3>Serotype</h3>
<p><strong>C-ANCA &amp; P-ANCA</strong></p>
<p>Indirect immunofluorescence (IIF): microscopic technique, result is
positive or negative with some descriptive qualifiers</p>
<ul>
<li>C-ANCA is typically a diffuse fine granular labeling of the
cytoplasm that is accentuated between the nuclear lobes</li>
<li>P-ANCA yields a finely rimmed, homogeneous fluorescence staining of
the perinuclear cytoplasm. Labeling of the perinuclear cytoplasm by
p-ANCA is actually an artefact of ethanol fixation, which causes a
redistribution of the positively charged cytoplasmic granular proteins
to collapse onto the surface of the negatively charged nucleus.</li>
</ul>
<p><strong>Anti-MPO or Anti-PR3</strong></p>
<ul>
<li>Enzyme-linked immunosorbent assay (ELISA): will confirm an antigenic
target of the ANCA</li>
<li>Unclear the best diagnostic path – <a
href="https://pubmed.ncbi.nlm.nih.gov/27481830/">some groups</a>
advocate using ELISA exclusively , others feels <a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478512/">ELISAS</a>
are not yet suitable for screening due to the higher false neg rate
(~40% in this study case)</li>
</ul>
<p>Phenotypes</p>
<ul>
<li>C-ANCA are primarily present in sera from patients with Wegener’s
granulomatosis and mainly recognize proteinase 3.</li>
<li>P-ANCA are frequently detected in patients with microscopic
polyangiitis and most often react with myeloperoxidase.</li>
</ul>
<p><strong>False Positives are common</strong></p>
<ul>
<li>ANCA in ulcerative colitis (UC; 60–87%), primary sclerosing
cholangitis (PSC; 60–92%), autoimmune hepatitis (AIH; 50–96%) and, to a
lesser extent, Crohn’s disease (CD; 5–25%)</li>
<li>No cytoplasmic target yet identified in these GI cases - various
proposed names atypical p-ANCA’, ‘a-ANCA’ or ‘x-ANCA’. There is likely a
perinuclear target here, so perhaps atypical p-ANCA’, ‘a-ANCA’ or
’perinuclear antineutrophil nuclear antibodies (<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906166/#:~:text=The%20staining%20patterns%20produced%20by,only%20label%20the%20perinuclear%20cytoplasm.">p-ANNA</a>)</li>
</ul>
<div class="float">
<img src="images/GN_age_freq.png"
alt="Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628710/" />
<div class="figcaption">Source: <a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628710/"
class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628710/</a></div>
</div>
<table>
<thead>
<tr class="header">
<th><strong>Characteristic</strong></th>
<th><strong>RLV n=121</strong></th>
<th><strong>MPA n=264</strong></th>
<th><strong>GPA n=117</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Diagnosis age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Mean±SD</td>
<td>59.8±18.4</td>
<td>57.5±18.1</td>
<td>47.9±19.8</td>
</tr>
<tr class="odd">
<td>Median (IQR)</td>
<td>66 (50, 73)</td>
<td>61 (49, 71)</td>
<td>50 (32, 64)</td>
</tr>
<tr class="even">
<td>MPO/PR3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>MPO</td>
<td>98 (81.0%)</td>
<td>155 (58.7%)</td>
<td>30 (25.6%)</td>
</tr>
<tr class="even">
<td>PR3</td>
<td>23 (19.0%)</td>
<td>109 (41.3%)</td>
<td>87 (74.4%)</td>
</tr>
<tr class="odd">
<td>Kidney involvement</td>
<td>121 (100%)</td>
<td>262 (99.2%)</td>
<td>105 (89.7%)</td>
</tr>
<tr class="even">
<td>Lung involvement</td>
<td>0 (0%)</td>
<td>157 (59.5%)</td>
<td>95 (81.2%)</td>
</tr>
<tr class="odd">
<td>ENT involvement</td>
<td>0 (0%)</td>
<td>97 (36.7%)</td>
<td>88 (75.2%)</td>
</tr>
</tbody>
</table>
<p>Source: <a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628710/"
class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628710/</a>(
adapted)</p>
<ul>
<li>Notes:
<ul>
<li>90% sensitive i.e. 10% of clinical phenotypes will be ANCA
negative.</li>
<li>Skin biopsies are useless, nonspecific leukocytoclastic.</li>
<li><strong>Be alert for overlap</strong> with both antiGBM and immune
complex disease e.g MN, LN, IGAN – always test for ANCA and antiGBM
together</li>
<li>Consider the predilection for elderly but don’t miss the rare young
ones.</li>
<li>Dual positive MPO and PR3 – rare, consider drug induced
e.g. Hydralazine.</li>
<li>PR3 OR higher in Men, tend to be younger, higher eGFR</li>
<li>OR of being PR3 increases from South to North i.e with decreasing <a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365766/">UV
radiation</a></li>
</ul></li>
</ul>
</div>
</div>
<div id="anca-anti-gbm-dual-positive" class="section level2">
<h2>ANCA &amp; anti GBM dual positive</h2>
<p>Renal Outcomes more similar to Anti GBM</p>
<p><strong>Immune complex</strong></p>
<ul>
<li>Anti GBM
<ul>
<li>In situ immune complex formation</li>
<li>Linear IF staining</li>
<li>Highly restricted to small vessels</li>
<li><strong>Never causes arteritis</strong> – i.e. if you see arteritis
in anti GBM disease its probably coexisting ANCA vasculitis.</li>
</ul></li>
<li>IGA Vasculitis
<ul>
<li>Systemic - IgA Dominant vessel wall deposits</li>
<li>anti IgA1 may be relevant in future</li>
</ul></li>
<li>Cryoglobulinaemic
<ul>
<li>Cryoglobulins in blood and vessel</li>
<li>Hypocomplementic</li>
<li>High Rh factors can support</li>
<li>Skin, gloms and peripheral nerves classic</li>
</ul></li>
<li>Anti c1q (hypocomplementaemia urticarial vasculitis)
<ul>
<li>Hypocomplementic</li>
<li>Circulating anti C1q antibodies</li>
<li>GN resembles lupus nephritis</li>
<li>GN, uveitis and episcleritis are common</li>
</ul></li>
</ul>
<p>Variable: Cogans, Bechet’s</p>
<p>Single organ: Cutaneous small vessel vasculitis, primary CNS</p>
<p>Systemic disease : Rh, Lupus, Sarcoid</p>
<p><strong>Misc</strong></p>
<ul>
<li>HBV – range of presentations – from PAN to Small vessel ANCA
like</li>
<li>Drugs – dual positive classic</li>
</ul>
<p>Infectious</p>
<ul>
<li>Bacterial</li>
<li>Rickettsial (e.g. Rocky Mountain Spotted Fever – Dog tick, derm
vasculitis, If+)</li>
<li>Viral</li>
<li>Fungal</li>
</ul>
</div>
<div id="treatment" class="section level2">
<h2>Treatment</h2>
<p>Don’t wait for a biopsy to start treatment if unwell and convincing
clinical picture</p>
<ul>
<li>ANCA present in 90% of Pauci immune GN, and Bx has a diagnostic
yield of about 90%</li>
<li>10% persistently ANCA negative,</li>
<li>Hunt for organ involvement – CT CAP, echo, full exam + further
directed tests</li>
<li>Ensure no reason for false positive (NB: infection, Endocarditis
etc)</li>
<li>Sclerosis is a poor prognostic sign</li>
<li><strong>Do not withhold</strong> induction on the basis of
unfavourable histology as recovery despite seemingly advanced disease is
possible</li>
</ul>
</div>
<div id="initial-induction" class="section level2">
<h2>Initial induction</h2>
<p>Image for regimes</p>
<p><strong>Glucocorticoids &amp; Ritux/cylophos</strong></p>
<ul>
<li><p>Cylcophos: RPGN, aggressive disease (pulmonary, neuro), Cr
&gt;354</p>
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/26621483/">CYCLOPS</a>:
IV=PO for remission, 50% less exposure, less leukopaenia, more
relapse</li>
</ul></li>
<li><p>Ritux: PR3 (<a
href="https://pubmed.ncbi.nlm.nih.gov/26621483/">RAVE</a>, OR 2.11 for
remission), children, frail older, sparing steroids, fertility concerns,
bladder cancer. <a
href="https://pubmed.ncbi.nlm.nih.gov/26621483/">RAVE</a> excluded
severe AKI &gt;350.</p></li>
<li><p>Combo: <a
href="https://pubmed.ncbi.nlm.nih.gov/20647198/">RITUXIVAS</a> –
375mg/m2 weekly *4, CTX pulse 15mg/kg with ritux#1 nd #3 == 6/12 CTX
&amp; AZA</p></li>
<li><p>PEX: <a
href="https://pubmed.ncbi.nlm.nih.gov/17582159/">MEPEX</a> ( Cr&gt;500
ARR 6%), Consider for Cr &gt;300 (ARR 4.6%), requiring HD, pulmonary
haemorrhage, GBM overlap. <a
href="https://pubmed.ncbi.nlm.nih.gov/30612116/">PEXIVAS</a> didn’t show
benefit in eGFR &lt;50 or pul haem (and increased infections), <a
href="https://www.bmj.com/content/376/bmj-2021-064604.abstract">meta-analysis</a>
suggests might still be worth it.</p>
<p>Nonsevere disease only:</p></li>
<li><p>MMF: <a
href="https://pubmed.ncbi.nlm.nih.gov/30612116/">MYCYC</a> non life
threatening, no RPGN, induction=CTX, much higher PR3 relapse.</p></li>
<li><p>MTX: non Renal disease, but high relapse</p></li>
<li><p>AVACOPAN: <a
href="https://pubmed.ncbi.nlm.nih.gov/33596356/">ADVOCATE</a> – non
serious disease as pred alternative. Less SE, maybe a little better for
albuminuria. Maybe.</p></li>
</ul>
<p><strong>Never forget</strong></p>
<ul>
<li>Pre induction check: TB (quantiferon gold), HIV, HBV, HCV,
Strongloides</li>
<li>TMP-SMX for PJP</li>
<li>IgG levels baseline and 6monthly with ritux.</li>
</ul>
<p><strong>Dose</strong> <img src="images/AAV%20IS%20regimes.jpg"
alt="Source: KDIGO24" /></p>
</div>
<div id="maintanence" class="section level2">
<h2>Maintanence</h2>
<p><strong>Remission:</strong> (BVAS=0, stable or improved eGFR, may
have persistent urine changes)</p>
<p><strong>Duration:</strong> 18 months – 4 years. Options: Ritux vs Aza
(MMF) &amp; pred wean</p>
<p>Ritux</p>
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/29695500/">MAINRITSAN</a>
(vs aza – less major relapses, not minor) – 500mg*2 at remission, and
500mg at month 6, 12, 18.</li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/36958796/">RITZAZREM</a>
(relapse, vs aza less major and minor) – 1g post induction, and month
4,8,12,16.</li>
<li>Can dose as fixed or by CD19 cells ( same relapse rates, lower
overall doses)</li>
</ul>
<p>Aza</p>
<ul>
<li>1.5-2mg/kg/day at remission for 1 year, then drop by 25mg every 3
months.</li>
<li>1.5-2mg/kg/day for 18-24 months, then drop 1mg/kg/day for 4 years,
then taper 25mg every 3 months. Pred 5-7.5 for 2 years then drop 1mg/2
months.</li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/36958796/">AZA-ANCA</a>: 2
vs 4 years – relapse of 48 vs 24%</li>
<li>MMF if intolerant. ( 1g bd for 2 years)</li>
</ul>
<p>If still on HD at 3 months – consider discontinuation if no
manifestations</p>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/30612116/">PEXIVAS</a> taper
( as effective as high dose, less SE):</p>
<div class="float">
<img src="images/pexivas_steroid_taper.jpg" alt="Source: KDIGO24" />
<div class="figcaption">Source: KDIGO24</div>
</div>
</div>
<div id="relapse-refractory" class="section level2">
<h2>Relapse &amp; Refractory</h2>
<ul>
<li>Relapse risk: GPA, PR3, ENT, multiple organs, history of relapse,
residual ANCA positive, rise in ANCA, IS withdrawal.</li>
<li>Unclear risk – persistent haematuria? May lead to relapse</li>
<li>Return of haematuria when previously absent may indicate
relapse</li>
<li>Ritux best for relapse (<a
href="https://pubmed.ncbi.nlm.nih.gov/26621483/">RAVE</a>)</li>
<li>Refractory: try the ritux/cylo option not initially used. PEX if
tricky.</li>
</ul>
</div>
<div id="tips" class="section level2">
<h2>Tips</h2>
<ul>
<li>Tx: Remission for 6 months. ANCA persistence no barrier.</li>
<li>Relapse rate post tx 0.02-0.03 per patient year</li>
<li>50% have persistent haemato/proteinuria</li>
<li>Histological activity is unlikely in the absence of haematuria</li>
<li>5% GBM +</li>
<li>32% of GBM are ANCA +</li>
</ul>
<div id="post-remission-rising-in-anca" class="section level3">
<h3>Post remission rising in ANCA</h3>
<p>Per Stegeman on the ASN forums:</p>
<ul>
<li>In general a significant rise in ANCA titer, either PR3 or MPO, over
a period of 3-6 months is associated with a risk of relapse of around
60% in the 6-12 months following the ANCA rise.</li>
<li>The other 40% will not have a relapse of disease over a period of
1-2 years.</li>
<li>What a significant rise in ANCA is, is totally dependent on the test
used (indirect immune fluorescent tests usually at least a fourfold rise
(2 titer steps); ELISA based methods 75-100% increase and 2-3 times the
upper limit of normal (so changes in the very low positive range usually
mean not much) and should be analyzed for the test you are using to
quantify ANCA levels.</li>
<li>In our experience a continuous slow rise in ANCA (so less than a
significant rise in 3-6 months or over a longer period) does not have
much prognostic value above the baseline risk of ~10-20% annual risk of
relapse associated with persistent positive PR3-ANCA in the first 5
years after diagnosis and initial treatment (for MPO-ANCA the risk seems
lower probably more around 5-10%)</li>
</ul>
<p>So I would advise not to treat an isoloated (significant!) rise in
ANCA titer unless you want to minimize the risk of relapse to the
absolute minimum (because you fear the consequences of the relapse for
the patient, which seems not be the case for this particular patient
(given the bothersome but not lifethreatening manifestations of her
disease and the fact that most relapses copy the initial presentation
and it is unusual (unfortunately not impossible) to have more
extensive/severe disease manifestations during relapse as compared to
the previous presentations).</p>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = false;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
